ZNF717 and amyotrophic lateral sclerosis: MuSK agonism using different Fz-domain binding antibodies (X17 or Mab13) have so far improved symptoms of muscle weakness in animal models for genetic neuromuscular disorders such as SMA, ALS and DOK7 CMS.31